A mechanistic study showed that it enhanced the AR-V7 protein degradation via the ubiquitin-proteasome pathway in prostate cancer cells at 0.5-1.0 μM without affecting the full-length AR protein (116). The gene discussed is AR; the disease is prostate carcinoma.